6-丙基烟醛 | 143142-34-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-丙基烟醛
• 英文名称: 6-propylnicotinaldehyde
• 英文别名: 6-propylpyridine-3-carbaldehyde
• CAS: 143142-34-1
• 化学式: C₉H₁₁NO
• mdl: MFCD18804180
• 分子量: 149.192
• InChiKey: FKWPVUNGBPPVTL-UHFFFAOYSA-N

物化性质

• 沸点：
  249.9±20.0 °C(Predicted)
• 密度：
  1.038±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-丙基烟醛 在 哌啶 、 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 、 吡啶 为溶剂， 生成
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

  摘要：

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.

  DOI：

  10.1021/jm00123a012
• 作为产物：
  描述：

  6-氯烟酸甲酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 、 palladium on activated charcoal 、 氢气 、 异丙基氯化镁 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 甲苯 为溶剂， -78.0~80.0 ℃ 、137.9 kPa 条件下， 反应 16.5h， 生成 6-丙基烟醛
  参考文献：
  名称：

  ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS

  摘要：

  Formula I的化合物作为MGAT2抑制剂，可用于预防、治疗或作为高脂血症、糖尿病和肥胖的治疗药物。

  公开号：

  US20180009796A1

文献信息

• [EN] PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES<br/>[FR] PYRIDO[4,3-B]INDOLES CONTENANT DES FRAGMENTS RIGIDES
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2010051501A1

  公开（公告）日：2010-05-06

  This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及具有刚性基团的吡啶并[4,3-b]吲哚化合物。在一个实施例中，这些化合物是具有不饱和碳氢基团的吡啶并[4,3-b]吲哚化合物。在另一个实施例中，这些化合物是具有环烷基、环烯基或杂环基团的吡啶并[4,3-b]吲哚化合物。还提供了包括这些化合物的药物组合物，以及使用这些化合物在各种治疗应用中的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• Diastereoselective and Highly Enantioselective Henry Reactions using C1-Symmetrical Copper(II) Complexes
  作者：Antoinette Chougnet、Guoqi Zhang、Kegang Liu、Daniel Häussinger、Andreas Kägi、Thomas Allmendinger、Wolf-D. Woggon

  DOI：10.1002/adsc.201100157

  日期：2011.7

  Catalytic Henry reactions of aliphatic aldehydes and prochiral nitro compounds were investigated using copper(II) complexes of 14 C1‐symmetrical ligands derived from (1R,2R)(−)‐diaminocyclohexane. β‐Nitro alcohols with syn:anti ratios of up to 5.7 and excellent ee values for both diastereosimers were obtained.

  使用衍生自（1 R，2 R）（-）-二氨基环己烷的14 C 1对称配体的铜（II）配合物研究了脂肪醛和前手性硝基化合物的催化亨利反应。β硝基醇与顺式：反向上的比率5.7和优异的ee值获得两个diastereosimers值。
• Non-Flushing Niacin Analogues, and Methods of Use Thereof
  申请人：Bachovchin William W.

  公开号：US20090312355A1

  公开（公告）日：2009-12-17

  One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.

  本发明的一个方面涉及取代吡啶及其药学上可接受的盐，对一系列哺乳动物疾病具有活性。本发明的另一个方面涉及一种制药组合物，包括本发明的化合物或其药学上可接受的盐，以及药学上可接受的载体。本发明还涉及治疗一系列哺乳动物疾病或病症的方法，包括但不限于高脂血症、高胆固醇血症、动脉粥样硬化、冠状动脉疾病、充血性心力衰竭、心血管疾病、高血压、冠心病、心绞痛、糙皮病、哈特努普综合征、类癌综合征、动脉闭塞性疾病、肥胖症、甲状腺功能减退症、血管收缩、骨关节炎、类风湿性关节炎、糖尿病、阿尔茨海默病、脂肪萎缩症或血脂异常，提高血清高密度脂蛋白（HDL）水平，降低血清低密度脂蛋白（LDL）水平。
• PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES
  申请人：HUNG David T.

  公开号：US20100216814A1

  公开（公告）日：2010-08-26

  This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本文揭示了具有刚性基团的吡啶并[4,3-b]吲哚。在一种实施例中，化合物是具有不饱和碳氢基团的吡啶并[4,3-b]吲哚。在另一种实施例中，化合物是具有环烷基，环烯基或杂环基团的吡啶并[4,3-b]吲哚。还提供了包括这些化合物的制药组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍，精神障碍，神经递质介导的障碍和/或神经元障碍。
• Pyrido[4,3-B]indoles containing rigid moieties
  申请人：Medivation Technologies, Inc.

  公开号：US08906925B2

  公开（公告）日：2014-12-09

  This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及具有刚性基团的吡啶并[4,3-b]吲哚。在一种实施例中，化合物是具有不饱和碳氢基团的吡啶并[4,3-b]吲哚。在另一种实施例中，化合物是具有环烷基，环烯基或杂环基团的吡啶并[4,3-b]吲哚。还提供了包含该化合物的制药组合物，以及使用该化合物在多种治疗应用中的方法，包括治疗认知障碍，精神疾病，神经递质介导的疾病和/或神经元疾病。